[{"orgOrder":0,"company":"Orexo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nalmefene Hydrochloride","moa":"Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Orexo \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Orexo \/ Inapplicable"},{"orgOrder":0,"company":"Gabather","sponsor":"Centre for Neuropsychiatric Schizophrenia Research","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"GT-002","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Gabather","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Gabather \/ Centre for Neuropsychiatric Schizophrenia Research","highestDevelopmentStatusID":"6","companyTruncated":"Gabather \/ Centre for Neuropsychiatric Schizophrenia Research"},{"orgOrder":0,"company":"Gabather","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"GT-002","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Gabather","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Gabather \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gabather \/ Inapplicable"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The collaboration aims to support the clinical advancement of GT-002, which is a small molecule GABAA receptor-positive allosteric Modulator. Currently, it is being evaluated for schizophrenia.

                          Product Name : GT-002

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          October 04, 2024

                          Lead Product(s) : GT-002

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase I

                          Sponsor : Centre for Neuropsychiatric Schizophrenia Research

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : GT-002 is an oral small molecule GABAA receptor PAM eliciting both tonic and phasic inhibitory currents. It restores ketamine induced cognitive deficits in patients with schizophrenia.

                          Product Name : GT-002

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 03, 2024

                          Lead Product(s) : GT-002

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : OX124 is a powerful naloxone rescue medication, designed to reverse opioid overdoses, including those from highly potent synthetic opioids, such as fentanyl.

                          Product Name : OX124

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          July 16, 2021

                          Lead Product(s) : Naloxone Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The study was a cross-over, comparative bioavailability study in healthy volunteers to assess nalmefene absorption from three development formulations of OX125, Orexo's wholly-owned nasal nalmefene product, compared to a nalmefene intramuscular injection...

                          Product Name : OX125

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 30, 2020

                          Lead Product(s) : Nalmefene Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank